What is Dermlab?
Dermlab, operating under the broader DermPathGroup umbrella, is a prominent provider of dermatopathology services. Formed through the strategic merger of SkinDx and DermLab, the company leverages a state-of-the-art laboratory in Birmingham, AL. Its extensive team comprises over 240 subspecialty expert pathologists, including 14 board-certified dermatopathologists, enabling comprehensive anatomic, clinical, and molecular pathology services. Dermlab is dedicated to delivering precise and prompt diagnostic insights to dermatologists and healthcare providers, aiming to elevate patient outcomes through collaborative efforts and advanced technological integration. The company's mission centers on being a reliable diagnostic partner, enhancing the quality of care for individuals with skin conditions across 14 states.
How much funding has Dermlab raised?
Dermlab has raised a total of $987K across 2 funding rounds:
Debt
$350K
Debt
$637K
Debt (2020): $350K with participation from PPP
Debt (2021): $637K led by PPP
What's next for Dermlab?
The recent major strategic investment signifies a pivotal moment for Dermlab, likely positioning the company for accelerated expansion and enhanced service offerings. This capital infusion is expected to fuel further technological advancements in their diagnostic capabilities and potentially broaden their geographic reach. The company's focus on subspecialty expertise and advanced pathology services suggests a strategic direction towards solidifying its leadership in the dermatopathology market, potentially exploring new service lines or deepening existing partnerships within the healthcare ecosystem.
See full Dermlab company page
